Knowledge, attitudes, and practices remain relevant for disease management among patients with anemia.

These data indicate the benefits of implementing individual protective measures in winter by patients with COPD.

Igor Barjaktarevic, MD, PhD, discusses the evolving treatment landscape in COPD, highlighting current treatment approaches and novel therapies on the horizon.

Experts on respiratory diseases discuss the GOLD treatment guidelines for COPD and discuss research that is informing treatment strategies.

During SLEEP 2024, Judite Blanc, PhD, discussed her team’s ongoing study assessing whether an education VR program improves maternal stress and sleep among women of color.

Patients in the active counseling group were more likely to achieve low disease activity or remission.

Kaitlin Mayne, MBChB, discusses an analysis of the EMPA-Kidney trial examining the effects of multimorbidity, polypharmacy, and quality of life on effects of empagliflozin.

8 weeks of treatment with combination bemnifosbuvir and ruzasvir showed a 97% SVR rate at 12 weeks post-treatment in a phase 2 lead-in cohort.

At SLEEP 2024, Broussard told HCPLive about how eating time restriction can serve as another as another dietary tool for people who are unsuccessful with other strategies.

Broussard discussed the importance of eating during the day at SLEEP 2024.

High-impact chronic pain is a severely affected subgroup in SCD and is associated with greater pain burden and worse health outcomes.

The panel discusses strategies to predict patients who will have poor adherence to their HIV medications and how to select the best treatment options for them.

Experts on HIV provide clinical insights on testing for drug resistance prior to treatment and approaching the topic of resistance with patients.

These data suggest that those with psoriasis maintain an innate psychological vulnerability, indicating the necessity of addressing mental well-being in the disease’s management.

A study found that only 0.32% of 1.2 million patients underwent Lp(a) testing, with non-Hispanic Black and Hispanic patients significantly less likely to receive the test compared to White patients.

Survodutide, a glucagon/GLP-1 receptor dual agonist, improved MASH with no worsening of fibrosis, reduced liver fat content, and improved fibrosis by ≥ 1 stage in a phase 2 trial.

Participants said the process was easy, convenient, and informed their self-management behaviors.

A lower FACIT-Fatigue score, indicating higher fatigue was independently associated with female sex, a high BMI, a high stress level, and poor sleep quality.

Alexandra Louise Møller, MS, PhD, discusses the results of a PROVALID analysis examining the predictive value of endotrophin levels for predicting CKD events.

The investigators looked at patients whose severity improved based on either the Physician Global Assessment or the modified Localized Scleroderma Severity Index.

This analysis looked at the efficacy and safety of 200-mg of orally-administered abrocitinib at a rate of once daily, highlighting the drug’s use among patients with CPUO or PN.

The Council recommends the elimination of unnecessary clinical efficacy trials and establishing global regulatory comparators.

Anjali Tiku Owens, MD, shares insights into how their institution or clinic implements the Risk Evaluation and Mitigation Strategy (REMS) program for mavacamten, detailing the requirements and responsibilities of the patient in the process. Additionally, the expert draws upon their real-world experience with the cardio myosin inhibitor (CMI) in clinical practice, providing valuable perspectives on the practical application of this novel drug class.

File joins Lungcast to review the ATS-IDSA 2019 guideline updates for community-acquired pneumonia, and advances to diagnostics and care.

Mona Shahriari, MD, discusses how she foresees the role of nonsteroidal topical creams growing within the management of plaque psoriasis.